Amy Wilson joined Stroock s Intellectual Property Group in 2002 as a Technical Consultant and registered patent agent. She was a post-doctoral fellow at Memorial Sloan-Kettering Cancer Center, where she studied cancer biology and gene regulation. From there Dr. Wilson joined Synaptic Pharmaceutical, a biotechnology company, where she was involved in early stage drug discovery. After three and a half years at Synaptic, Dr. Wilson joined The Society for Biomolecular Screening (SBS) as the Associate Director of Education and Communication. She was responsible for all of the scientific content of The Society and as such interacted with scientists and business leaders from the pharmaceutical and biotechnology sectors. Dr. Wilson has continued her active involvement in SBS as a former Chairperson and current member of its Academic Outreach Committee, which promotes interaction and communication between the drug discovery industries and academia. Dr. Wilson s work at Stroock is concentrated on life science patent prosecution, including biologics and drug discovery assay technologies. She also assists Stroock attorneys with IP investigations, the strategic counseling of emerging biotech and pharmaceutical companies, and life science related corporate transactions. Member, Academic Outreach Committee, Society for Biomolecular Screening; Speaker, Association for Laboratory Automation s ALALabFusion 2004 Conference, Boston, June 2004, Commercialization of Emerging Companies; Speaker and Co-Organizer, Academic and Industrial Approaches to HTS & Drug Discovery Conference, Harvard University, May 2004; Co-author: The Supreme Court & Integra Life Sciences v. Merck Kga4 Decision: Adverse Effect on the Relationship between Big Pharma and Biotech? , LabtoWallStreet, December 2005; Co-author, Intellectual Property Issues Surrounding Stem Cell Research, LabToWallStreet, Vol. 4, Issue 2, 2005; Co-author, A Patent Law Perspective: Is Expedited Approval of Biogenerics Around the Corner? LabToWallStreet, Vol. 3, Issue 3, 2004; Quoted in BioWorld article, High Court Offers Opinion, But Merck-Integra Fight Remanded regarding implications to the pharmaceutical and biotechnology industries; Co-author, The Intellectual Property (IP) Audit: An Effective IP Asset Management Tool, Journal of Biomolecular Screening, Vol. 8 No. 1, 2003; Co-author, Leveraging IP Helps Biotechs Raise Capital, SBS News, September 2002; Co-author, Collaborating with Academia: What You Need to Know, Journal of Biomolecular Screening, Vol. 7 No. 4, 2002 Ph.D., University of Kentucky, 1994; Molecular Biology